Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclincal Model of NASH at the AASLD 2016 Liver Meeting

NEWARK, Calif., Oct. 06, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases...
October 05, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis

NEWARK, Calif., Oct. 05, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases...
September 08, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

NEWARK, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat diseases with high...
August 09, 2016 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Second Quarter 2016 Financial Results

NEWARK, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat diseases with high...
August 02, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay to Announce Second Quarter 2016 Financial Results on Tuesday, August 9

NEWARK, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high...
July 07, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Participation at Cantor Fitzgerald Healthcare Conference on July 12th in New York

NEWARK, Calif., July 07, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high...
May 31, 2016 07:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)

Study stopped early after review of safety and efficacy data demonstrated clear proof-of-concept and opportunity for further dose reduction to optimize clinical safety and efficacyLarge...
May 19, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at UBS Global Healthcare Conference

NEWARK, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high...
May 11, 2016 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports First Quarter 2016 Financial Results

NEWARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases...
May 02, 2016 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay to Announce First Quarter 2016 Financial Results on Wednesday, May 11

NEWARK, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high...